Introduction
============

Tuberculosis (TB) causes a large degree of suffering and an estimated 1.3 million deaths per year globally, occurring mainly in less affluent countries, but also in upper-middle and high-income countries in the European Union/European Economic Area (EU/EEA) \[[@r1],[@r2]\]. In Europe, there has been a steady decline in TB notification rates of ca 5% per year. Nevertheless, TB remains a considerable problem because of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB \[[@r3]\].

The main public health response to the TB epidemic consists of early diagnosis, prevention of transmission and adequate treatment. In general, treatment is most successful when there is no resistance to any of the drugs designated for treatment of TB \[[@r4]\], and the drugs isoniazid (INH) and rifampicin (RIF) can be included in the treatment regimen. INH has long been an essential component of first-line treatment for active TB and an important drug in TB control because of its potent early bactericidal activity, low rate of adverse events and low cost \[[@r5]\]. Currently, there is no equivalent alternative available \[[@r6]\]. Resistance to INH is prevalent \[[@r4]\], with substantial geographic variation \[[@r7]\].

INH mono-resistance increases the likelihood of negative treatment outcome and progression to MDR TB \[[@r4],[@r8],[@r9]\]. Reported treatment outcome seems to differ by setting and region for cases with INH-resistant TB \[[@r10]-[@r12]\]. Population groups that are especially at risk of negative treatment outcome due to INH mono-resistance are children and HIV-positive patients \[[@r13]-[@r15]\]. Recently, two systematic reviews assessed treatment options for INH mono-resistant TB \[[@r8],[@r16]\]. One review concluded that treatment with first-line drugs resulted in suboptimal outcome \[[@r8]\], whereas the other showed that extending the duration of RIF and increasing the number of effective drugs lowered the odds of unfavourable outcome \[[@r16]\]. An analysis of individual patient data conducted in the framework of a World Health Organization (WHO) guideline development process showed that the addition of a fluoroquinolone to a regimen of 6 months of daily RIF, ethambutol (EMB) and pyrazinamide (PZA) was associated with improved treatment success in INH-resistant cases \[[@r17]\]. After an evaluation of all available evidence, WHO has issued new guidelines on treatment for patients with INH mono-resistance \[[@r18]\]. Discussion is ongoing as to whether to maintain INH in the treatment regimen if a low degree of resistance is detected; however, there is limited data on the effect this strategy has on treatment outcome.

The European Surveillance System (TESSy), hosted by the European Centre for Disease Prevention and Control (ECDC), contains case-based information for more than 1.5 million TB cases reported by EU/EEA countries between 1995--2015 \[[@r3]\]. In contrast to the information from randomised controlled trials (RCTs) and cohort studies that were included in the systematic reviews, TESSy includes information on treatment outcome obtained in a programmatic setting \[[@r8],[@r16]\]. These data are from a larger number of patients, are more recent and are more EU/EEA-focused than the data in the aforementioned reviews. We therefore set out to analyse this dataset to determine the current treatment outcome of INH mono-resistant TB in the EU/EEA and to identify risk factors for unsuccessful treatment outcome in cases with INH mono-resistance.

Methods
=======

Study population and data sources
---------------------------------

In this observational study, we retrospectively analysed TB notification data reported to the TESSy database between 2002--14. We included pulmonary and extra-pulmonary TB cases with available information on treatment outcome and drug-susceptibility testing (DST) results for at least INH, RIF, streptomycin (STR) and EMB. Information on DST for PZA was not collected in TESSy during the study period and therefore PZA was not part of our inclusion criteria.

Operational definitions
-----------------------

Treatment outcome was reported 12, 24 and 36 months after the start of TB treatment. We categorised treatment outcome in accordance with the 2017 joint WHO Regional Office for Europe/ECDC surveillance and monitoring report \[[@r3]\]. For cases with a treatment outcome of 'still on treatment' at 12 or 24 months, the final treatment outcome reported at 24 or 36 months was used, respectively. Unadjusted data was stratified by age, although this stratification was not described in the protocol for this study. The operational definitions used in this study are listed in the Box.

###### Operational definitions for analysis of European tuberculosis surveillance data, 2002--2014

The following definitions were used:

• INH mono-resistant TB cases: cases with resistance to INH and documented susceptibility to RIF, STR and EMB;

• Cases with fully drug-susceptible TB: cases with documented susceptibility to INH, RIF, STR and EMB;

• New TB cases: cases who were never previously treated for TB or who received drug treatment for less than 1 month;

• Cases with a history of TB: cases who were previously treated for TB for 1 month or more (for countries who did not report information about previous treatment, the variable previous diagnosis was used as a proxy);

• Geographical origin of cases, i.e. native vs foreign: based on the country of birth or, if this information was unavailable, on the citizenship of the patient;

• Low TB-incidence country: country with a TB incidence rate \< 10 cases per 100,000 population \[[@r31]\];

• High TB-incidence country: country with a TB incidence rate ≥ 10 cases per 100,000 population \[[@r31]\].

EMB: ethambutol; INH: isoniazid; RIF: rifampicin; STR: streptomycin; TB: tuberculosis.

Statistical analysis and modelling approach
-------------------------------------------

To investigate the impact of INH mono-resistant TB compared with fully drug-susceptible TB on treatment success, we applied a multilevel logistic regression model. To adjust for the heterogeneity between countries, the model was corrected with a random intercept at the country level for the differences in the average treatment success rate between countries and with a random slope for the differences in the INH mono-resistance effect on the treatment success rate at the country level. The necessity of adding a random intercept and a random slope in the model was determined using the likelihood-ratio test. The main outcome was dichotomised as unsuccessful treatment (failed, died, lost to follow-up and not evaluated) vs treatment success (cured or completed), using the final reported treatment outcome. Independent variables available in the TESSy data (age, sex, geographical origin, type of TB, microscopic confirmation, history of TB, HIV status and reporting year) were also assessed as possible confounders in the relationship between INH mono-resistant TB and treatment success. Independent variables that caused a change in the regression coefficient between INH mono-resistant TB and treatment success of \> 10% were considered potential confounders and were retained in the final multilevel multivariable model. In addition, we evaluated the interaction of INH mono-resistant TB with age and history of TB on treatment success at a p value of 0.1. Furthermore, a sensitivity analysis was conducted to assess the impact of INH mono-resistance after excluding cases with the outcome 'not evaluated'.

To identify risk factors for an unsuccessful treatment outcome in INH mono-resistant cases, the multilevel univariate and multivariable logistic regression models were used to examine the association between predicting variables (age, sex, geographical origin, microscopy confirmation, history of TB, HIV status, type of TB and reporting year) and unsuccessful treatment outcome. Age was dichotomised into \< and ≥ the median age of the included study population. In a sensitivity analysis, cases with the outcome 'not evaluated' were excluded. As the outcomes were proportions, we used logistic regression for all models. Odds ratios (OR) with 95% confidence intervals (CI) were calculated to assess the strength of the association. All analyses were performed using the STATA (Stata/SE 14.1, StataCorp LP, Texas, United States (US)) software.

Ethical statement
-----------------

This study is based on data collected on the basis of statutory notification in each EU/EEA country and reported anonymously to ECDC on the basis of decision No 2119/98/EC of the European Parliament and of the Council \[[@r19]\]. Therefore, informed consent from patients is not required.

Results
=======

Characteristics of the study population
---------------------------------------

From 2002--14, a total of 1,008,818 TB cases were notified in 31 EU/EEA countries and reported to TESSy. TB cases without reported treatment outcome for the years 2002--14 (n = 164,625) or who were diagnosed post-mortem (n = 4,031) were excluded from our analysis. We also excluded 618,291 TB cases without DST results for INH, RIF, EMB or STR. Furthermore, we excluded cases with drug resistance other than INH mono-resistance (n = 26,923). The remaining 194,948 TB cases from 24 EU/EEA countries fulfilled the inclusion criteria and were therefore eligible for our analysis. Of them, 7,578 (3.9%) were cases with INH mono-resistant TB ([Figure 1](#f1){ref-type="fig"}). Differences in the characteristics of included and excluded cases are presented in [Table 1](#t1){ref-type="table"}. No change in the proportion of INH mono-resistant TB was observed during the study period (Trend analyses: p value = 0.30).
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###### Characteristics of tuberculosis cases, by excluded and included cases, 31 EU/EEA countries, 2002--2014 (n = 1,008,818)

  Characteristics                                  Excluded TB cases   Included TB cases   p value^a^               
  ------------------------------------------------ ------------------- ------------------- ------------- ---------- -----------
  **Total**                                        **813,870**         **80.7**            **194,948**   **19.3**   --
  Median age in years (IQR)                        43 (30--58)         NA                  45 (32--60)   NA         0.05
  Male sex                                         522,843             64.3                127,642       65.5       0.91
  Cases of foreign origin                          172,776             22.4                56,451        29.3       0.51
  Extra-pulmonary TB                               177,592             21.9                28,032        14.4       0.11
  New TB cases                                     638,026             78.4                163,546       83.9       0.02
  Microscopic confirmation                         296,127             48.3                93,560        61.2       \< 0.01
  Positive HIV status                              4,976               0.6                 1,248         0.6        0.68
  **Proportion of cases by reporting countries**                                                                    
  Austria                                          4,771               44.6                5,919         55.4       p \< 0.01
  Belgium^b^                                       13,830              100                 0             0          
  Bulgaria                                         14,542              71.9                5,695         28.1       
  Croatia                                          619                 38.9                972           61.1       
  Cyprus                                           328                 57.3                244           42.7       
  Czech Republic                                   4,927               46.4                5,704         53.7       
  Denmark                                          4,086               82.9                843           17.1       
  Estonia                                          2,927               50.9                2,826         49.1       
  Finland                                          2,577               58.7                1,817         41.3       
  France^c^                                        70,140              100                 0             0          
  Germany                                          28,524              41.6                40,015        58.4       
  Greece^d^                                        7,911               100                 0             0          
  Hungary                                          17,720              78.4                4,879         21.6       
  Iceland                                          137                 97.8                3             2.2        
  Ireland                                          3,660               67.0                1,803         33.0       
  Italy^c^                                         56,146              100                 0             0          
  Latvia                                           7,533               47.8                8,209         52.2       
  Liechtenstein^d^                                 5                   100                 0             0          
  Lithuania                                        13,572              51.9                12,570        48.1       
  Luxembourg^d^                                    443                 100                 0             0          
  Malta                                            305                 68.9                138           31.2       
  Netherlands                                      8,314               59.0                5,769         41.0       
  Norway                                           1,450               34.4                2,771         65.6       
  Poland                                           70,917              64.3                39,430        35.7       
  Portugal                                         24,906              60.5                16,241        39.5       
  Romania                                          311,991             98.9                3,265         1.1        
  Slovenia                                         432                 15.4                2,372         84.6       
  Slovakia                                         4,189               52.6                3,783         47.4       
  Spain^c^                                         54,232              100                 0             0          
  Sweden                                           5,881               82.3                1,264         17.7       
  UK                                               76,855              73.0                28,416        27.0       

EU/EEA: European Union/European Economic Area; HIV: human immunodeficiency virus; IQR: interquartile range; TB: tuberculosis; TESSy: The European Surveillance System; UK: United Kingdom.

^a^ Obtained by a multivariable logistic regression model corrected for clustering within countries.

^b^ Not performing drug susceptibility testing for streptomycin.

^c^ Not reporting case-based drug susceptibility data and treatment outcome data.

^d^ Not reporting treatment outcome data.

Data source: TESSy.

The majority of included cases were reported by Germany, Poland and the United Kingdom (UK) (20.5%, 20.2% and 14.6%, respectively). Cases with INH mono-resistant TB were more likely to be younger than cases with fully drug-susceptible TB (median age 41 vs 46 years), be of foreign origin (37.0% vs 28.6%) and have a prior history of TB (13.6% vs 9.4%). Cases with INH mono-resistant TB were also more frequently reported by high TB-incidence countries, compared with low TB-incidence countries (65.9% vs 60.0%) ([Table 2](#t2){ref-type="table"}).

###### Characteristics of tuberculosis cases by isoniazid mono-resistance status, 24 EU/EEA countries, 2002--2014 (n = 194,948)

  ----------------------------------------------------------------------------------------------------------------
  Characteristics                                  Fully susceptible\   INH mono-resistant\                 
                                                   TB cases^a^          TB cases                            
  ------------------------------------------------ -------------------- --------------------- ------------- ------
  Total                                            187,370              NA                    7,578         NA

  **Sex**                                                                                                   

  Female                                           64,640               34.5                  2,566         33.8

  Male                                             122,636              65.4                  5,006         66.1

  Unknown                                          94                   0.1                   6             0.1

  **Age (years)**                                                                                           

  Median (IQR)                                     46 (32--60)          NA                    41 (30--54)   NA

  **Age group**                                                                                             

  \< 15                                            3,160                1.7                   174           2.3

  15--44                                           89,845               47.9                  4,346         57.3

  45--64                                           57,172               30.5                  2,202         29.0

  \> 64                                            37,127               19.8                  855           11.3

  Unknown                                          66                   0.1                   1             0.1

  **Geographical origin**                                                                                   

  Native                                           131,344              70.1                  4,639         61.2

  Foreign                                          53,648               28.6                  2,803         37.0

  Unknown                                          2,378                1.3                   136           1.8

  **Type of TB**                                                                                            

  Pulmonary                                        160,231              85.5                  6,341         83.7

  Extra-pulmonary                                  26,813               14.3                  1,219         16.1

  Unknown                                          326                  0.2                   18            0.2

  **Sputum smear microscopy**                                                                               

  Negative                                         57,063               30.4                  2,183         28.8

  Positive                                         89,898               47.9                  3,662         48.3

  Unknown                                          40,409               21.7                  1,733         22.9

  **History of TB**                                                                                         

  New TB case                                      157,526              84.1                  6,020         79.4

  Case with history of TB                          17,634               9.4                   1,027         13.6

  Case with unknown TB history                     12,210               6.5                   531           7.0

  **HIV status**                                                                                            

  Negative                                         17,624               9.4                   823           10.9

  Positive                                         1,203                0.6                   45            0.6

  Unknown                                          168,543              90.0                  6,710         88.5

  **EU/EEA countries**                                                                                      

  Low TB incidence                                 74,742               40.0                  2,582         34.1

  High TB incidence^b^                             112,628              60.0                  4,996         65.9

  **Reporting years**                                                                                       

  2002--2005                                       49,532               26.4                  2,089         27.6

  2006--2009                                       61,478               32.8                  2,403         31.8

  2010--2014                                       76,360               40.8                  3,086         40.6

  **Number of TB cases by reporting country^c^**                                                            

  Austria                                          5,716                96.6                  203           3.4

  Bulgaria                                         5,416                95.1                  279           4.9

  Croatia                                          953                  98.0                  19            2.0

  Cyprus                                           224                  91.8                  20            8.2

  Czech Republic                                   5,626                98.6                  78            1.4

  Denmark                                          807                  95.7                  36            4.3

  Estonia                                          2,721                96.3                  105           3.7

  Finland                                          1,759                96.8                  58            3.2

  Germany                                          38,700               96.7                  1,315         3.3

  Hungary                                          4,663                95.6                  216           4.4

  Iceland                                          1                    33.3                  2             66.7

  Ireland                                          1,725                95.7                  78            4.3

  Latvia                                           7,648                93.1                  561           7.4

  Lithuania                                        11,790               93.8                  780           6.2

  Malta                                            136                  98.5                  2             1.5

  Netherlands                                      5,508                95.5                  261           4.5

  Norway                                           2,630                94.9                  141           5.1

  Poland                                           38,579               97.8                  851           2.2

  Portugal                                         15,764               97.1                  477           2.9

  Romania                                          3,032                92.9                  233           7.1

  Slovenia                                         2,346                98.9                  26            1.1

  Slovakia                                         3,697                97.7                  86            2.3

  Sweden                                           1,204                95.3                  60            4.7

  UK                                               26,725               94.1                  1,691         5.6

  **Final treatment outcome**                                                                               

  Treatment success                                144,961              77.4                  5,611         74.0

  Death                                            14,681               7.8                   516           6.8

  Failed                                           1,111                0.6                   102           1.4

  Lost to follow-up                                10,259               5.5                   567           7.5

  Not evaluated                                    16,358               8.7                   782           10.3
  ----------------------------------------------------------------------------------------------------------------

EU/EEA: European Union/European Economic Area; INH: isoniazid; IQR: interquartile range; NA: not applicable; TB: tuberculosis; TESSy: The European Surveillance System; UK: United Kingdom.

^a^ TB cases susceptible to at least isoniazid, rifampicin, ethambutol and streptomycin.

^b^ High-incidence countries were defined as those with 10 or more TB cases per 100,000 population in 2015 (Bulgaria, Croatia, Estonia, Latvia, Lithuania, Poland, Portugal, Romania and the UK).

^c^ Seven countries (Belgium, France, Greece, Italy, Liechtenstein, Luxembourg and Spain) were excluded from this study, as they did not report treatment outcome and/or the required susceptibility data.

Data source: TESSy.

Tuberculosis treatment outcome
------------------------------

At 12 months after the start of treatment, INH mono-resistant TB cases had a lower TB treatment success rate than cases with fully susceptible TB (67.7% (5,131/7,578) vs 75.8% (142,051/187,370)). Noticeably, a higher proportion of cases 'still on treatment' was observed among INH mono-resistant TB cases in comparison to fully susceptible TB cases (9.8% (745/7,578) vs 3.0% (5,651/187,370), respectively). The treatment success rate was still lower in INH mono-resistant TB cases compared with fully susceptible TB cases (74.0% vs 77.4%), when assessing the final reported treatment outcome ([Table 2](#t2){ref-type="table"}). Fewer INH mono-resistant cases died while being treated for TB, compared with fully susceptible TB cases (6.8% vs 7.8%) ([Table 2](#t2){ref-type="table"}). However, a higher proportion of cases with treatment failure was observed among INH mono-resistant TB cases in comparison to fully susceptible TB cases (1.4% vs 0.6%, respectively) ([Table 2](#t2){ref-type="table"}). Unknown treatment outcome (i.e. lost to follow-up and not evaluated) was documented for 17.8% of INH mono-resistant TB cases vs 14.2% of fully susceptible TB cases ([Table 2](#t2){ref-type="table"}, [Figure 2](#f2){ref-type="fig"}).

![Treatment outcome of tuberculosis, by isoniazid mono-resistance status, 24 EU/EEA countries, 2002--2014 (n = 194,948)](1800392-f2){#f2}

For cases younger than the median age of 45 years, the final treatment success rates were 76.6% (3,341/4,362) for INH mono-resistant TB and 82.6% (73,960/89,536) for susceptible TB. For cases aged ≥ 45 years, the treatment success rate decreased for both case groups; however, the difference was smaller (70.6% (2,270/3,216) for INH mono-resistant TB vs 72.6% (71,001/97,834) for fully susceptible TB). Treatment outcome by age group and INH mono-resistance status are presented in [Figure 3a](#f3){ref-type="fig"}. The treatment success rate varied between countries for both fully susceptible and INH mono-resistant TB cases. Markedly, a relatively high proportion of deaths during TB treatment was reported among INH mono-resistant TB cases in Croatia (21.1%) and Slovenia (19.2%). In Romania and Hungary, a high proportion of cases with treatment failure was observed (12.0% and 10.2%, respectively) ([Figure 3b](#f3){ref-type="fig"}).
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Impact of INH mono-resistance on tuberculosis treatment success
---------------------------------------------------------------

In the univariate model corrected for clustering within countries, INH mono-resistance was associated with a lower TB treatment success compared with cases with fully susceptible TB (OR: 0.8; 95% CI: 0.7--0.9). Out of all statistically evaluated covariates, adding age, microscopic confirmation or history of TB to the crude model led to the predefined change (\> 10%) in the regression coefficient for INH mono-resistance and, therefore, these covariates were retained in the multivariable model as potential confounders. No interactions of INH mono-resistant TB with age (p value = 0.9) or history of TB treatment (p value = 0.2) were observed; therefore, these variables were not included in the final model.

In the final multivariable model, treatment success among INH mono-resistant TB was lower compared with fully drug-susceptible TB (adjusted OR: 0.7; 95% CI: 0.6--0.9). This corresponds to an adjusted treatment success of 74.0% for INH mono-resistant TB and 79.3% for fully susceptible TB, adjusted absolute difference of 5.3% ([Supplementary Table S1](/content/10.2807/1560-7917.ES.2019.24.12.1800392#supplementary_data)). The treatment success remained lower among INH mono-resistant TB compared with fully susceptible TB in the multivariable model after excluding cases with 'not evaluated' as treatment outcome (OR: 0.7; 95% CI: 0.6--0.8) (data not shown).

Factors associated with unsuccessful final treatment outcome of INH mono-resistant tuberculosis cases
-----------------------------------------------------------------------------------------------------

In the multivariable model adjusted for heterogeneity between countries, unsuccessful treatment among INH mono-resistant TB cases was associated with age ≥ median age (41 years) (OR: 1.3; 95% CI: 1.2--1.5), male sex (OR: 1.3 95%; CI: 1.1--1.4), positive microscopy (OR: 1.3; 95% CI: 1.1--1.4), history of TB (OR: 1.8; 95% CI: 1.5--2.2) and positive HIV status (OR: 3.3; 95% CI: 1.6--6.5) ([Figure 4](#f4){ref-type="fig"}) ([Supplementary Table S2](/content/10.2807/1560-7917.ES.2019.24.12.1800392#supplementary_data)). In the sensitivity analysis, excluding cases with the treatment outcome 'not evaluated', no change in the associated risk factors was observed (data not shown).
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INH mono-resistant and fully susceptible TB shared the same risk factors for unsuccessful treatment, except for being of foreign origin, which was associated with a higher risk for unsuccessful treatment in fully susceptible but not INH mono-resistant TB cases in the multivariable model (data not shown).

Discussion
==========

Our retrospective study of European surveillance data, including 7,578 cases of INH mono-resistant TB and 187,370 cases of fully susceptible TB, shows that INH mono-resistance is associated with lower TB treatment success in the final TB treatment outcome. This association between INH mono-resistance and lower treatment success is in line with a previous systematic review \[[@r20]\]. Although this review was published in 2009, it includes many studies that were published before the year 2000 and were mainly conducted in countries in Asia and Africa. The same applies to the reviews evaluating treatment regimens for INH mono-resistant TB that were published in 2016 \[[@r16]\] and 2017 \[[@r8]\], respectively. Therefore, our analysis of more recent 2002--14 EU/EEA surveillance data represents an addition to the currently available evidence.

Studies of TB treatment outcome under routine programmatic conditions have shown inconsistent results regarding treatment outcome of INH mono-resistant TB. While studies from the US \[[@r10]\], Denmark \[[@r12]\] and Israel \[[@r21]\] reported treatment outcome for INH mono-resistant TB as excellent, highly successful or similar to drug-susceptible TB, studies from Peru \[[@r22]\], Mexico \[[@r23]\], Georgia \[[@r24]\] and South Africa \[[@r11]\] showed poorer treatment outcome compared with fully susceptible TB. Possible explanations might be differences in the included patient populations; for example, regarding HIV prevalence \[[@r11],[@r12]\], the availability of resources for patients, the accessibility of healthcare systems or the use of different treatment regimens. Our study, which pools data from 24 low HIV-prevalence and predominantly high-income European countries, shows that INH mono-resistance negatively affects treatment outcome. The study findings also highlight the need for timely identification of patients with INH mono-resistant TB, especially as rapid testing in recent years has focused more on the detection of RIF resistance as a proxy for MDR TB \[[@r6]\].

Comparison of studies has been hampered by different definitions used for INH mono-resistance. While many studies retained all INH resistance profiles, provided that RIF resistance and therefore MDR TB was excluded \[[@r8],[@r16]\], other studies required additional documented susceptibility for STR and EMB \[[@r23]\] or analysed INH mono-resistant and INH poly-resistant cases with additional resistance to STR or EMB separately \[[@r12]\]. To avoid misclassification, we have used the stricter definition requiring documented DST results for INH, RIF, STR and EMB for all cases. However, while gaining specificity in the definition of INH mono-resistance, this approach has resulted in the loss of a large number of cases for which these susceptibility testing results were not available, with considerable differences in the percentages of cases that could be included by country.

The finding that EU/EEA countries have different proportions of patients with INH mono-resistant TB still under treatment at 12 months might be a surveillance artefact related to variation in reporting procedures or the result of the use of different treatment regimens with different durations, reflecting the current lack of an agreed standard regimen for the treatment of INH mono-resistant TB cases \[[@r18],[@r25],[@r26]\]. As the 12-month outcome therefore did not seem to be the most adequate endpoint for analysis of the treatment outcome of INH mono-resistant TB, we chose a composite outcome for this study using the final documented outcome irrespective of the time to reporting (12 months, 24 months or 36 months after the start of treatment).

The factors found to be associated with a higher risk of unsuccessful treatment outcome in INH mono-resistant TB in this study--higher age, male sex, positive microscopy, positive HIV status--have been described before as associated with unsuccessful TB treatment outcome independent of drug resistance status \[[@r27],[@r28]\]. Prior TB treatment has also been reported as a risk factor for unsuccessful outcome in patients with INH mono-resistant TB \[[@r29]\]. In our study, these factors influenced TB treatment outcome regardless of the presence or absence of INH mono-resistance, indicating that they are not specific to INH mono-resistant TB, but rather are associated with lower TB treatment success in general.

The strengths of our study are the inclusion of a large number of cases and the application of a multilevel model to correct for TB clustering. This allowed to control for possible selection bias related to reporting countries and for unobserved heterogeneity between countries, thereby enhancing the generalisability of our findings. However, there are also several limitations to our study, mainly related to the use of surveillance data collected with the aim to inform TB programme management and not to evaluate clinical outcomes. As a result, data on the severity of TB disease, underlying diseases and treatment regimens were not available.

In addition, information on DST for PZA is not available in the TESSy data. In a sensitivity analysis using German notification data (40,063 TB cases, of which 1,310 were INH mono-resistant) that include information on DST for PZA, cases resistant to PZA were more frequent among INH mono-resistant TB compared with otherwise fully susceptible TB cases (5.4% vs 1.8%; p \< 0.01). However, no impact of the PZA resistance status on the relationship between INH mono-resistant TB and treatment success was observed (adjusted OR: 0.8; 95% CI: 0.6--1.4; p = 0.77). Another limitation related to DST is that no information is available on the level of INH-resistance and the type of INH resistance mutations involved, which have been shown to influence treatment outcome \[[@r30]\].

Lastly, our study included data from only 24 of 31 EU/EEA countries; cases from seven countries were excluded due to lack of reporting treatment outcome or case-based susceptibility data ([Table 1](#t1){ref-type="table"}). Therefore, our data pertain only to these 24 EU/EEA countries and cannot be generalised to the whole EU/EEA without caution. Of note, 80.7% of reported cases had to be excluded due to missing information. As systematic reasons for lack of reporting within the 24 countries with included cases are not known, it is not possible for us to hypothesise how this might have affected our findings.

In conclusion, this study shows that treatment of patients with INH mono-resistant TB under routine programme conditions leads to lower treatment success compared with fully susceptible TB. The association of INH mono-resistance with negative treatment outcome highlights the need to pay increased attention to the timely identification and management of these cases to ensure treatment success for individual patients, as well as to reduce the risk for further resistance development on a population level.
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Click here for additional data file.

[^1]: Correspondence: Anke Kohlenberg (<anke.kohlenberg@ecdc.europa.eu>)
